,,,
, , , , -,
? ? ?
, , , ; , .
. .
; , 75% .
, , , , ().
, , . , , .
, , , , . . ; . ( , , , .)
. , , . , , , [3].
. (. 1), .
1. .
,
-
/ /
- . , .
- , , . . .
: 0,7 .
0,15 ( , ).
. . ( Owen Mumford, Brook Hill, Woodstock, Oxford OX20 1TU).
, , . ( , , , ), , .
, .
, *
,
,
,
,
,
( )
* , , - .
( ), , , , ( ). .
. , , [5]. , , .
. , . .
, , ( ) ( ). . ( ).
, , , .
, [6]. , , , ( ).
. -2- , , . , . , .
101 . 37% , ( 5,4 ) . 15% , , [7]. , , , 10-20 30 .
, 40% , . Martin Dale Pharmaceyticals (UK) 5 10 . 10 20 .
, . . , , , , . , , , , .
. ( 1), , . . , , . , . .
, , , .
. . 26 , . , , ; , .
. , . , 140 20% , 112 (80%) . (42%). .
.
. , 50% . , , . , , 6 , , , [9]. 24 . , .
, .
. [10]. - 1511 ; 996 (66%) , . .
(65% 19%). , 7 10 . , , , , , . .
. . [11,12]. (, 3% , 0,25% 0,05% ), [13]. .
( / ) .
. . , ().
, , . . [14,15] .
1. Feldman H. A., Goldstein, Hatzichristou D. J., et al. Impotence and its medical and psychological correlates: Results of the Massachusetts male aging study. J. Urol 1994; 151:54.
2. Price D. E. Managing inpotence in diabetes. B. M. J. 1993; 307:275.
3. NIH, Consensus Development Panel of Impotence, JAMA 1993; 280:8392.
4. Goldstein I., Siroky M. B., et al. Vasculogenic impotence: Role of the pelvic steal test. J. Urol. 1982; 128:300306.
5. Bhasin S. Androgen treatment of hypogonadal men. J. Clin. Endocrinol. Metab. 1992; 74:1221.
6. Herman J. B., Brotman A. W., Pollack M. H., et al. Fluoxetine induced sexial dysfunction. J. Clin. Psychiatry 1990; 51:25.
7. Riley A. J., Goodman R. E., Kellett J. M., et al. Double blind trial of yohimbine hydrichloride in erection inadequacy. J. Sexual Material Therapy 1989; 4:17.
8. Weiss J. N., Badiani G. H., Ravalli R., Brettschneider N. Reasons for high drop-out rate with self-injection therapy for impotence. Int. J. Impot. Res. 1994; 6:171.
9. Carson C. C. 3rd, Mino R.D. Priaprism assotiated with trazodone therapt. J. Urol. 1988; 139:369.
10. Padma-Natham H., Hellstrom W. J., Kaiser F. E., et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N. Engl. J. Med. 1997; 336:17.
11. Class H., Baert L. Transcutaneous nitroglycerin therapy in the treatment of impotence. Urol. Int. 1989; 44:309 312.
12. Cavallini G. Minoxidil versus nitroglycerin: a prospective doubleblind controlled trial in transcutaneous erection facilitation for organic impotence. J. Urol. 1991; 146:50 53.
13. Gomaa, Shalaby M., Osman M., et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate. B. M. J. 1996; 312:1512 1515.
14. Boolell M., Allen M., Ballard S., et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. of Inpotence Research 1996; 8:47 52.
15. Boolell M., Gepi-Attee J.,C., Gingell, Allen M. Sildenenfil, a novel effective oral therapy for male erectile dysfunction. B. J. Urol. 1996; 78:257 261.
Copyright (c) 2025 Stud-Baza.ru , , , .